Posted on February 26, 2019 by Sitemaster
We know that both abiraterone acetate (Zytiga) and enzalutamide (Xtandi) can be used to extend the survival of men with mCRPC who have already been treated with docetaxel + prednisone. However, … READ MORE …
Filed under: Uncategorized | Tagged: castration-resistant, CHEIRON, combination, docetaxel, enzalutamide, mCRPC, metastatic, trial | Leave a comment »
Posted on December 27, 2018 by Sitemaster
A new paper in the Journal of Clinical Oncology has just reported that the overall survival (OS) of black and white men diagnosed with metastatic castration-resistant prostate cancer (mCRPC) seems to be near to identical after treatment with docetaxel or a docetaxel-containing regimen. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: black, castration-resistant, docetaxel, mCRPC, metastatic, race, survival, white | Leave a comment »
Posted on October 21, 2018 by Sitemaster
New data from the ongoing STAMPEDE trial in the UK and Switzerland has now confirmed that ablative radiation of the prostate itself (debulking of the primary tumor) improves overall survival (OS) in men newly diagnosed with metastatic prostate cancer who have a low metastatic disease burden but not in those with higher burden of disease. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Treatment | Tagged: ADT, androgen, debulking, deprivation, docetaxel, metastasis, primary, radiation, therapy, tumor | 7 Comments »
Posted on September 25, 2017 by Sitemaster
A new study in BJU International has shown the importance of waiting at least 3 weeks after initiation of androgen deprivation therapy (ADT) until initiation of docetaxel chemotherapy in the treatment of men with newly diagnosed, metastatic, hormone-sensitive prostate cancer (mHSPC). … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Treatment | Tagged: ADT, androgen, chemotherapy, deprivation, docetaxel, hormone-sensitive, metastatic, neutropenia, risk, timing | 2 Comments »
Posted on September 12, 2017 by Sitemaster
In another presentation from the ESMO meeting in Madrid, Spain, Fizazi et al. presented data from the randomized CABA-DOC trial exploring patients’ preferences for either docetaxel or cabazitaxel as a first-line form of chemotherapy. … READ MORE …
Filed under: Management, Treatment | Tagged: cabazitaxel, chemotherapy, choice, docetaxel, preference, taxane | 2 Comments »
Posted on September 11, 2017 by Sitemaster
A presentation at the ongoing annual meeting of the European Society of Medical Oncology (ESMO), in Madrid, Spain, has offered us data comparing abiraterone acetate + prednisone + ADT to docetaxel + ADT in the treatment of men with high-risk, metastatic, hormone-sensitive prostate cancer (mHSPC). … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone, ADT, androgen deprivation, docetaxel, hormone-sensitive, metastatic, mHSPC | 4 Comments »
Posted on August 25, 2017 by Sitemaster
The results of two recent, large clinical trials may have some impact on the clinical use of cabazitaxel (Jevtana) in the treatment of late-stage prostate cancer. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: cabazitaxel, docetaxel, dosing, Jevtana, outcome, Taxotere | 3 Comments »
Posted on August 29, 2016 by Sitemaster
A new paper in JAMA Oncology has suggested that longer docetaxel-based chemotherapy may be associated with longer survival for at least some men being treated for metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: castration-resistant, chemotherapy, cycles, docetaxel, mCRPC, metastatic, survival | 8 Comments »
Posted on June 7, 2016 by Sitemaster
One of the small number of major prostate cancer presentations at the ASCO meeting this year comes from the so-called PRINCE trial of intermittent chemotherapy in men with castration-resistant prostate cancer (CRPC). … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: chemotherapy, continuous, docetaxel, intermittent, outcome | 5 Comments »
Posted on May 11, 2016 by Sitemaster
A paper presented yesterday at the now-completed annual meeting of the American Urological Association has given us new data on the role of adjuvant chemotherapy alone in the treatment of men with high-risk prostate cancer. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: "high risk", adjuvant, chemotherapy, docetaxel, prostatectomy | Leave a comment »
Posted on March 21, 2016 by Sitemaster
Drugs like docetaxel and cabazitaxel (taxanes) are among the most active forms of treatment in the management of men with metastatic, castration-resistant prostate cancer (mCRPC), but they don’t work for everyone. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Risk, Treatment | Tagged: cabazitaxel, docetaxel, expression, gene, taxane, TMPRSS2-ERG | Leave a comment »
Posted on February 2, 2016 by Sitemaster
Some 2½ years ago, James presented data from the TRAPEZE trial at the annual meeting of the American Society of Clinical Oncology in Chicago. At the time, we described these data as “unsurprising.” … READ MORE …
Filed under: Management, Treatment | Tagged: catration-resistant, docetaxel, mCRPC, metastatic, outcome, strontium-89, TRAPEZE, zoledronic acid | Leave a comment »
Posted on January 6, 2016 by Sitemaster
As regular readers will be aware, the data from the CHAARTED trial were the first to show that combining androgen deprivation (ADT) with docetaxel chemotherapy has a significant, life-extending benefit in at least some men newly diagnosed with metastatic prostate cancer. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, androgen, CHAARTED, deprivation, docetaxel, quality of life | 1 Comment »
Posted on December 25, 2015 by Sitemaster
Back in May 2015, James et al. reported on the survival benefits associated with androgen deprivation therapy (ADT) + docetaxel-based chemotherapy compared to ADT alone as first-line therapy for treatment-naive men initially diagnosed with metastatic prostate cancer. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, chemotherapy, docetaxel, hormone-naive, metastatic, STAMPEDE | 4 Comments »
Posted on December 2, 2015 by Sitemaster
Another paper at the European Cancer Congress this year has given us meta-analyses of data from studies of docetaxel chemotherapy + standard of care (i.e., some form of androgen deprivation therapy or ADT) in treatment of men newly diagnosed with metastatic (M1) and advanced but non-metastatic (M0) prostate cancer. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, androgen, deprivation, docetaxel, meta-analysis, metastatic | 1 Comment »
THE "NEW" PROSTATE CANCER INFOLINK 